ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)


Volume 17, 9 Issues, 2017


Download PDF Flyer




Current Cancer Drug Targets

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 68th of 213 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.992
5 - Year: 3.412

Upcoming Articles (E-Pub Abstracts ahead of Print)

Regulation of microRNAs by phytochemicals: a promising strategy for cancer chemoprevention


Sadegh Babashah, Babak Bakhshinejad, Maryam Tahmasebi Birgani , Katayoon Pakravan and William C Cho.


View Abstract


Therapeutic approaches for the treatment of epidermal growth factor receptor mutated lung cancer


Dhaval Sanchala, Lokesh K Bhatt and Kedar S Prabhavalkar.


View Abstract


Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer


Heena Singla, Anjana Munshi, Raja Paramjit Singh Banipal and Vinod Kumar.


View Abstract


The Structural Bioinformatics analysis of Biophenolic Lignan-Estrogen Receptor interaction


Farzaneh Mohamadyar-Toupkanlou, Mina Esfandiari, Mahshid Sadat Kashef-Saberi, Mahboubeh Kabiri Renani and Masoud Soleimani.


View Abstract


Evaluation of anti-cancer activity of stilbene and methoxydibenzo[b,f]oxepin derivatives


Damian Garbicz , Damian Mielecki , Michał Wrzesiński , Tomasz Pilżys, Michał Marcinkowski , Jan Piwowarski , Janusz Dębski, Ewelina Palak, Przemysław Szczeciński, Hanna Krawczyk and Elżbieta Grzesiuk.


View Abstract


Crizotinib versus chemotherapy on ALK-positive NSCLC :a systematic review of efficacy and safety


Mingxia Wang, Guanqi Wang, Haiyan Ma and Baoen Shan.


View Abstract


An update on circumventing multidrug resistance in cancer by targeting P-glycoprotein


Xiaoqian Yang, Xiaoduan Li, Zhenfeng Duan and Xipeng Wang.


View Abstract


Significant role of MUC1 in development of resistance to currently existing anti-cancer therapeutic agents


Leila Farahmand, Parnaz Merikhian, Neda Jalili, Behrad Darvishi and Keivan Majidza.


View Abstract


p53-Mdm2 interaction inhibitors as novel nongenotoxic anticancer agents


Surendra Kumar Nayak, Gopal L. Khatik, Rakesh Narang, Vikramdeep Monga and Harish Kumar Chopra.


View Abstract


Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer


Noreen Akhtar and Ishrat Jabeen.


View Abstract


Chemosensitizing activity of histone deacetylases inhibitory cyclic hydroxamic acids for combination chemotherapy of lymphatic leukemia


Denis V. Mishchenko, Margarita E. Neganova, Elena N. Klimanova, Tatyana E. Sashenkova, Elena F. Shevtsova, Igor V. Vystorop, Vadim V. Tarasov, Ghulam Md Ashraf , Nagendra Sastry Yarla and Gjumrakch Aliev.


View Abstract


JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells


Ilaria Zanellato, Donato Colangelo and Domenico Osella.


View Abstract


Fertility drugs and ovarian cancer


Aus Tariq Ali.


View Abstract


The Complexity of DEK Signaling in Cancer Progression


Yong Teng, Liwei lang and Catherine E Jauregui.


View Abstract


Cancer-targeted oncolytic adenoviruses for modulation of the immune system


Vincenzo Cerullo, Cristian Capasso, Markus Vähä-Koskela, Otto Hemminki and Akseli Hemminki.


View Abstract


Advertisement
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science